SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (210)7/9/1997 9:29:00 PM
From: John Zwiener   of 10280
 
Hi James, Hmmmmm,
I guess I had not thought through what that could mean to the stock price, but 200 might be reasonable, even if the racemeric form did not get pulled. But the antihistamine did get pulled, just because their MIGHT be an association with sudden death. I think albuterol also might have that association. It doesn't really matter because the isomer form appears to be better. If the FDA agrees, then why would one give an inferior drug to patients to "save" money. The patients would not appreciate it. Money is important with equivilent drugs, but if a drug is clearly superior, the better drug will always be given, even at an HMO or at the VA (well maybe at the latter).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News